Prevalence of Hypertrophic Cardiomyopathy in Highly Trained Athletes Relevance to Pre-Participation Screening by Basavarajaiah, Sandeep et al.
H
t
d
(
H
K
c
e
o
t
F
a
j
Y
2
Journal of the American College of Cardiology Vol. 51, No. 10, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PCardiomyopathy
Prevalence of Hypertrophic
Cardiomyopathy in Highly Trained Athletes
Relevance to Pre-Participation Screening
Sandeep Basavarajaiah, MBBS, MRCP,*† Matthew Wilson, MSC, MPHIL,‡ Gregory Whyte, PHD,‡
Ajay Shah, PHD, FRCP,* William McKenna, DSC, FRCP, FESC, FACC,§
Sanjay Sharma, BSC (HONS), MD, FRCP*†
London, England
Objectives This study sought to determine the prevalence of hypertrophic cardiomyopathy (HCM) in elite athletes.
Background Hypertrophic cardiomyopathy is considered to be the most common cause of exercise-related sudden death in
young athletes. The prevalence of HCM in elite athletes has never been reported but has important implications
with regard to pre-participation screening for the disorder.
Methods Between 1996 and 2006, 3,500 asymptomatic elite athletes (75% male) with a mean age of 20.5  5.8 years
(range 14 to 35 years) underwent 12-lead electrocardiography and 2-dimensional echocardiography. None had a
known family history of HCM.
Results Of the 3,500 athletes, 53 (1.5%) had left ventricular hypertrophy (mean 13.6  0.9, range 13 to 16), and of
these 50 had a dilated left ventricular cavity with normal diastolic function to indicate physiological left ventricu-
lar hypertrophy. Three (0.08%) athletes with left ventricular hypertrophy had a nondilated left ventricular cavity
and associated deep T-wave inversion that could have been consistent with HCM. However, none of the 3 ath-
letes had any other phenotypic features of HCM on further noninvasive testing and none had first-degree rela-
tives with features of HCM. One of the 3 athletes agreed to detrain for 12 weeks, which showed resolution of
electrocardiography and echocardiographic changes confirming physiologic left ventricular hypertrophy.
Conclusions The prevalence of HCM in highly trained athletes is extremely rare. Structural and functional changes associated
with HCM naturally select out most individuals from competitive sports. Screening athletes with echocardiogra-
phy is not cost effective. However, electrocardiography is useful in selecting out those individuals who may have
pathological left ventricular hypertrophy for subsequent echocardiography. (J Am Coll Cardiol 2008;51:
1033–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.055d
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iypertrophic cardiomyopathy (HCM) is considered to be
he most common cause of exercise-related sudden cardiac
eath (SCD) in young (35 years) athletes in the U.S.
1–4). The sudden death of some high-profile athletes of
CM has led some sporting organizations in the United
ingdom to implement relatively elaborate, independent
ardiovascular screening programs composed of 12-lead
lectrocardiography (ECG) and 2-dimensional echocardi-
graphy in all athletes to identify HCM. Indeed, given the
herapeutic strategies now available to prevent sudden
rom *King’s College Hospital; †University Hospital; ‡Olympic Medical Institute;
nd §The Heart Hospital, London, England. Dr. Basavarajaiah is supported by a
unior cardiac research fellow grant from the charity organization Cardiac Risk in the
oung.w
Manuscript received August 20, 2007; revised manuscript received October 24,
007, accepted October 29, 2007.eath, such as the implantable cardioverter-defibrillator, the
ecessity for early identification of HCM in athletes has
ecome magnified. In the United Kingdom and in many
ther developed countries, cardiovascular evaluation of ath-
etes is usually confined to athletes competing at the regional
r national level.
See page 1040
Although the prevalence of HCM in the general population
s 0.2% (5), the precise prevalence of HCM in the most highly
rained athletes is unknown. Calculations based on the Italian
re-participation screening program involving over 34,000
thletes indicate that the estimated prevalence of HCM in
ndividuals participating in regular organized sporting activity
s approximately 0.07% (6). However, data from this series
ere not confined specifically to elite athletes.
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HCM in Elite Athletes March 11, 2008:1033–9The aim of this study was to
determine the prevalence of
HCM in some of the most
highly ranked athletes in the
United Kingdom to aid in justi-
fication for or against screening
for HCM in this cohort.
Methods
Setting. Although there is no
formal government-sponsored
pre-participation screening pro-
ram in the United Kingdom, certain sporting bodies such
s the British Lawn Tennis Association, the Premiership
ootball and rugby league, and the national swimming and
oxing squads have adopted mandatory self-funded pre-
articipation screening programs for athletes comprising
ersonal, family, and drug history; physical examination;
2-lead ECG; and echocardiography with a view to further
nvestigations if necessary. Dr. Sharma has been responsible
or performing cardiovascular evaluation in elite athletes in
hese sporting disciplines since 1996 at St George’s Hospital
edical School, Olympic Medical Institute (Northwick
ark Hospital), University Hospital Lewisham, and King’s
ollege Hospital.
thletes. Between 1996 and 2006, 3,500 asymptomatic
lite athletes between 14 years and 35 years (mean age 20.5
ears) underwent 12-lead ECG and 2-dimensional trans-
horacic echocardiography as a part of pre-participation
creening for HCM. Of these, 2,625 (75%) were male and
75 (25%) were female. Just over 98% of athletes were
aucasian; the remainder were of West African decent. The
thletes had a mean body surface area of 1.86  0.16 m2
range 1.36 to 2.29 m2).
Written consent was obtained from individuals older than
6 years and from a parent or guardian for those younger
han 16 years. The athletes participated in 15 different
porting disciplines, but the vast majority of the study group
71%) represented football, rugby, tennis, and swimming
Table 1). The term elite was used in relation to achieve-
ents in the athletic arena; all athletes competed at the
egional level and approximately 60% at the national level
uring the study period.
Ethical approval for the study was granted by Harrow
esearch Ethics Committee to the Cardiac Risk in the
oung (CRY), Centre of Sports Cardiology.
CG. A standard 12-lead ECG examination was per-
ormed during quiet respiration in a supine position and
nalyzed using a Marquette Hellige (Milwaukee, Wiscon-
in) ECG recorder. The electrodes were placed carefully to
nsure consistency of the precordial lead locations, and
CGs were recorded at a paper speed of 25 mm/s. The PR
nterval; QRS duration; QT interval; QRS axis; Q-, R-, S-,
Abbreviations
and Acronyms
ECG  electrocardiography
HCM  hypertrophic
cardiomyopathy
LV  left
ventricle/ventricular
LVH  left ventricular
hypertrophy
SCD  sudden cardiac
deathnd T-wave voltage; and ST-segments were measured in oach lead using calipers and a millimeter ruler as described
lsewhere (7).
The QT intervals were corrected for the heart rate (QTc)
sing the Bazett formula (8). A QTc interval of440 ms in
en and 460 ms in women was considered abnormal.
Left ventricular (LV) hypertrophy (LVH) was defined by
he Sokolow-Lyon voltage criterion. The LVH was defined
y the sum of the S waves in V1 and the R waves in V5
xceeding 3.5 mV (9).
chocardiography. Two-dimensional echocardiography
as performed with the subjects resting in a left lateral
ecubitus position, using an Acuson Computed Sonograph
28XP/10c (San Jose, California) with 3-MHz transducer.
mages of the heart were obtained in the standard paraster-
al long-axis and short-axis and apical 4-chamber planes, as
reviously described (10). The LV wall thickness was
easured from 2-dimensional short-axis views in end dias-
ole, with the greatest measurement within the LV wall
efined as the maximal wall thickness.
M-mode echocardiograms derived from 2-dimensional
mages in the parasternal long axis were used for the
easurement of LV end-diastolic and -systolic dimensions,
eft atrial diameter, and aortic root according to American
ociety of Echocardiography standards (11). Three to 5
onsecutive measurements were taken, and the average was
alculated.
Percent LV shortening fraction was calculated as an index
f systolic function. Pulsed Doppler recordings were per-
ormed at the distal margins of mitral valve leaflets to
rovide an index of diastolic function (12).
riteria for consideration of the diagnosis of HCM in
thletes. Based on previous publications and our own
xperience of an athlete’s heart, athletes with a LV wall
hickness 12 mm were considered to have LVH (13–15).
thletes with LVH and a relatively nondilated LV in terms
istribution of Athletesn Relation t Sporting Discipline
Table 1 Distribution of Athletesin Relation to Sporting Discipline
Type of Sport Number of Athletes Percentage
Football 910 26
Tennis 788 22.5
Rugby 441 12.6
Swimming 344 9.8
Rowing 144 4.1
Hurling 95 2.7
Cycling 112 3.2
Athletics 112 3.2
Netball 91 2.6
Basketball 91 2.6
Badminton 95 2.7
Triathlon 91 2.6
Boxing 74 2.1
Fencing 56 1.6
Speed skating 56 1.6
Total 3,500f athletic training (56 mm) (16) in association with any
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March 11, 2008:1033–9 HCM in Elite Athletesne of the following were considered to have findings that
ould be consistent with pathological LVH rather than
hysiological hypertrophy: 1) impaired diastolic function
17); 2) enlarged left atrial diameter 45 mm in athletes
18 years old (18) and up to 50 mm in older athletes (19);
) LV outflow obstruction caused by systolic anterior
otion of the anterior mitral valve leaflet (20); 4) left bundle
ranch block (21); 5) ST-segment depression or deep
-wave inversions (0.2 mV) in 2 contiguous leads
except V1 and V2 in athletes age 16 years old) (22,23) on
he ECG; and 6) a family history of HCM in first-degree
elatives.
Athletes with a family history of HCM or those
howing the echocardiographic and/or ECG abnormali-
ies considered to represent pathological LVH were
nvestigated further with 48-h ECG (24), cardiopulmo-
ary exercise test (25), and cardiac magnetic resonance
maging (26) to evaluate the broader phenotype of HCM
nd to assess risk of SCD (27). The 48-h ECG was
erformed to check specifically for nonsustained ventric-
lar tachycardia. The cardiopulmonary test was per-
ormed to identify abnormalities in exercise blood pres-
ure response, exercise arrhythmias, and estimation of
eak oxygen consumption. The cardiac MRI scan was
erformed to exclude apical HCM.
In athletes with persisting diagnostic uncertainty after the
nvestigations above, first-degree relatives were invited for
creening for HCM and/or attempts were made to persuade
he individual to detrain for 3 months followed by repeat
valuation (28,29).
esults
one of the athletes in the study had a family history of
CM in first-degree relatives, and none had experienced
ngina, breathlessness disproportionate to the amount of
xercise performed, or exertional syncope.
The diagnosis of HCM was excluded by echocardiogra-
hy in 3,447 (98.5%) on the basis of a LV wall thickness
12 mm, absence of systolic anterior motion of the anterior
itral valve leaflet causing LV outflow obstruction, and
ormal diastolic function.
thletes with an LV wall thickness >12 mm (LVH). Of
he 3,500 athletes, 53 (1.5%) showed a maximal LV wall
hickness exceeding 12 mm and were considered to have
VH (Fig. 1) (16). All 53 athletes were male and repre-
ented a variety of ball, racket, and endurance sporting
isciplines, and all 53 participated in sport at the national
evel. The echocardiographic characteristics of these athletes
re shown (Table 2). None of the athletes with LVH had
ndexes of diastolic dysfunction, an enlarged left atrial
iameter, or systolic anterior motion of the anterior mitral
alve leaflet and associated LV outflow obstruction. Fifty of
he 53 athletes with LVH had an associated dilated LV and
ormal systolic function, consistent with physiological LVH
14,15). mTwenty athletes in this cohort had deep T-wave inver-
ions in at least 2 contiguous inferior and/or lateral leads.
one of the athletes with LVH had left bundle branch
lock or ST-segment depression in 2 or more contiguous
CG leads.
thletes with LVH and a nondilated LV. Only 3 of the
3 athletes with LVH had a nondilated LV, which could be
onsidered to represent morphologically mild HCM. None
f the athletes had any other echocardiographic features of
CM (Table 2). All 3 athletes also showed deep T-wave
nversions in inferior and/or lateral leads (Fig. 2). The 48-h
olter monitoring did not reveal any episodes of nonsus-
ained ventricular tachycardia or paroxysmal atrial fibrilla-
ion in any of the 3 athletes. All 3 athletes exercised to the
oint of volitional exhaustion and achieved 95% of the
redicted heart rate for age. All 3 athletes showed an
dequate blood pressure response to exercise and achieved
igh peak oxygen consumption and anaerobic threshold
alues (Table 3). Cardiac magnetic resonance scans using
adolinium-diethylenetriamene pentacetate (0.1 mmol/kg)
n all 3 athletes revealed normal left and right ventricular
tructure and function. In relation to the diagnosis of
CM, there was no evidence of apical HCM, marked
ypertrophy of anterolateral free wall, or myocardial fibrosis.
Both parents and siblings of all 3 athletes accepted
nvitations for screening for HCM with 12-lead ECG and
-dimensional echocardiography, which did not reveal any
onventional diagnostic features of the disorder to indicate
amilial disease.
Only 1 of the 3 athletes was persuaded to detrain for 3
onths, after which there was regression of LV hypertrophy
n echocardiography and resolution of the deep T-wave
nversion on the ECG (Fig. 3) (30). The 2 remaining athletes
eclined detraining through fear of team deselection and
ontinued to exercise. Both athletes agreed to be genotyped for
nown HCM-causing sarcomeric contractile protein gene
Figure 1 Distribution of LVWT in 3,500 Elite Athletes
We found that 1.5% of elite athletes showed a wall
thickness 12 mm. LVWT  left ventricular wall thickness.utations, which did not yield a diagnosis.
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HCM in Elite Athletes March 11, 2008:1033–9thletes with other cardiac abnormalities on ECG and
chocardiography. Twenty-six athletes (0.7%) had cardiac
iagnoses other than LV hypertrophy, including Wolff-
arkinson-White ECG pattern (n  6), isolated long QT
nterval (460 ms) (n  9), mitral valve prolapse (n  5),
chocardiographic Features in Athletesith Left Ventricular Wall Thickness >12 mm
Table 2 Echocardiographic Features in AthletesWith Left Ventricular Wall Thickness >12 mm
Mean  Standard Deviation (Range)
LVWTd (mm) 13.6 0.9 (13–16)
LVIDd (mm) 58.5 5.14 (45–65)
LVIDs (mm) 31.6 4.1 (22–42)
Left atrial diameter (mm) 32 4.8 (21–47)
E-wave (m/s) 0.87 0.2 (0.5–1.5)
A-wave (m/s) 0.45 0.2 (0.17–0.9)
E/A ratio 2.32 0.94 (1.8–4.5)
 late left ventricular filling; E  early left ventricular filling; LVIDd  maximal left ventricular
avity dimension in end diastole; LVIDs  left ventricular cavity dimensions in end systole; LVWTd
maximal left ventricular wall thickness in end diastole.
Figure 2 Electrocardiograms and Parasternal Short-Axis Views
at the Level of Papillary Muscle of the 3 Athletes Wit
All 3 athletes showed left ventricular hypertrophy (LVH) associated with a nondilattrial septal defect (n 2), bicuspid aortic valve (n 3), and
ortriatriatum (n  1) (31).
Thirty-five (1%) athletes showed deep T-wave inversions
n contiguous leads. Of these, 20 had LV hypertrophy (17
ith a dilated LV and 3 with a nondilated LV). The
emaining 15 (0.4%) athletes had deep T-wave inversions in
he absence of LV hypertrophy.
iscussion
revalence of HCM in elite athletes. Hypertrophic car-
iomyopathy is repeatedly cited as the leading cause of
udden death in young athletes (1–4). This cross-sectional
tudy shows that the prevalence of HCM in elite British
thletes is extremely low. Of the 3,500 athletes studied, only
(0.09%) athletes had LV morphology that could have been
egarded to be consistent with mild HCM after initial
valuation with ECG and echocardiography. However, in 1
f the 3 athletes, the diagnosis was excluded after demon-
tration of regression of LVH on echocardiography and
e LV
and a Nondilated LV Cavity
ventricular (LV) cavity and inferior and lateral leads.of th
h LVH
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March 11, 2008:1033–9 HCM in Elite Athletesssociated resolution of repolarization changes on ECG
30). The remaining 2 athletes had mild LVH and an
ssociated nondilated LV, but neither had any other mor-
hologic features of HCM or the broad phenotype of the
isorder on 48-h ECG monitoring and exercise stress
esting. Outside the context of familial disease, neither
thlete could be regarded as having unequivocal diagnostic
eatures of HCM.
Interestingly, both athletes were of West African decent,
hich may have had a bearing on the magnitude of hypertro-
hy in response to exercise and repolarization changes on the
CG (32). The 2 athletes in question also showed high
eak oxygen consumption and anaerobic threshold, indicat-
ng the ability to generate and sustain a large cardiac output
or prolonged periods. In contrast, most individuals with
CM (33), including those participating in regular physical
ctivity (34), have been shown to have low peak oxygen
onsumption irrespective of symptomatic status or magni-
ude of LVH. Genetic testing failed to identify a disease-
ausing mutation in both athletes, but based on the genetic
eterogeneity of HCM, the investigators concede that the
iagnosis of HCM cannot be excluded with certainty by a
egative genetic test.
Even if a diagnosis of HCM were entertained in the 2
thletes of West African ancestry above, the prevalence of
CM in elite athletes is no more than 0.06%, compared
ith 0.2% in the general population. The pathophysiolog-
cal manifestations of HCM, notably LVH, nondilated LV,
mpaired myocardial relaxation, myocardial ischemia, dy-
amic LV outflow obstruction, and mitral regurgitation, are
robably not conducive to achieving substantial increases in
ardiac stroke volume in most affected individuals. We
uspect that most individuals with HCM are selected out
rom competing in high-level sport where physical endur-
nce is a major component.
There were a significant number of athletes with LVH,
ut all had a dilated LV cavity, indicating physiological
VH. Although LV dilatation is also recognized in HCM,
t is usually a manifestation of end-stage disease and is
ssociated with New York Heart Association functional
lass III or IV (35).
udden death in sport attributed to HCM. Hypertrophic
ardiomyopathy is diagnosed at post-mortem examination
n some young high-profile athletes dying suddenly during
port. Whether all such deaths are based on the identifica-
ion of myocyte disarray, the histologic hallmark of HCM,
s uncertain, but reliance on macroscopic appearance and
ardiac weight alone has the potential for a false diagnosis of
CM in an athlete with physiological hypertrophy. The
talian pathologists from the center of excellence in the
eneto region have consistently reported fewer cases of
CM in athletes dying suddenly during sport compared
ith other nations, even before their screening program
36). A protagonist for HCM being the most common
ause of death in athletes would argue that there is a lowercluster of the HCM gene pool in the Mediterranean region;T
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HCM in Elite Athletes March 11, 2008:1033–9owever, an antagonist may argue that a thorough histologic
xamination of the heart by a cardiac pathology expert
xcludes HCM and identifies an alternative cause such as
rrhythmogenic right ventricular cardiomyopathy or an
ccessory pathway.
creening for HCM in elite athletes. Screening for HCM
pecifically with echocardiography in elite athletes is not
ost effective because several thousand athletes would have
o be screened to identify one with HCM. The investigators
oncede that HCM shows marked morphologic and func-
ional heterogeneity allowing a very small fraction of af-
ected individuals to compete at national and international
evels (37); however, this cannot justify large-scale screening
or HCM with echocardiography in all elite athletes. Fur-
her, certain genetic mutations show age-related penetrance,
herefore the absence of LVH in adolescence or young
dulthood does not rule out the possibility of developing
CM in the future (38).
Ironically the study identified 15 individuals with either the
olff-Parkinson-White ECG pattern (n  6) or a long QT
nterval (n  9), which are considered rare causes of SCD in
oung athletes (3) but may claim more lives in athletes than
riginally thought. Neither disorder precludes cardiac function
nd would not necessarily be selected out by intense physical
xertion. All athletes with the Wolff-Parkinson-White pattern
ad an identifiable accessory pathway that was ablated, per-
itting resumption of competitive sport. Of the 9 athletes with
long QTc interval, 3 were diagnosed with unequivocal long
T syndrome based on a Schwartz points score of 4 (n  2)
39), evidence of disease in a first-degree relative (n  2), or a
ositive genetic diagnosis (n  1) and were disqualified from
ompetitive sports. Diagnostic uncertainty persists with the
emaining 6, who have continued to compete for a mean
eriod of 3 years without adverse cardiac events.
Eleven athletes (0.3%) with a normal ECG showed minor
ongenital structural abnormalities that were not hemodynam-
cally significant and did not result in disqualification from
Figure 3 Electrocardiograms of a Swimmer With LVH and Infero
Detraining was associated with regression of left ventricular hypertrophy (LVH) onport. mOur experience suggests that screening elite athletes using
n ECG is more likely to identify individuals with other
onditions implicated in SCD and also to identify those
ho may have pathological LVH. The absence of ST-
egment depression, deep T-wave inversions, and left bun-
le branch block will exclude almost all cases of HCM as
hown by longitudinal follow-up of previously screened
talian athletes (40).
onclusions
he prevalence of HCM in elite athletes is significantly less
han in the general population; the demands of strenuous
xercise on the cardiovascular system select out most individ-
als with HCM. Screening all elite athletes with echocardiog-
aphy, the accepted gold-standard investigation for HCM, has
poor yield, with many thousand athletes needing to be
creened to identify a single individual with HCM. The ECG
s useful in identifying individuals who may have pathological
VH and other congenital electrical disorders that may prove
atal. Based on the British experience of systematic cardiovas-
ular screening of elite athletes, we propose that echocardiog-
aphy in athletes to screen for HCM should be reserved only
or athletes with symptoms suggestive of underlying cardiovas-
ular disease, a murmur indicative of LV outflow obstruction,
amily history of HCM in first-degree relatives or specific
CG changes, notably deep T-wave inversions, ST-segment
epression, pathological Q waves, left bundle branch block, or
xtreme leftward cardiac axis (23,41). Our study reveals that
nly 1% of athletes in this study would be expected to undergo
chocardiography to exclude HCM based on the proposed
ecommendations, which has a massive cost-saving implica-
ion, particularly for financially less endowed sporting clubs.
tudy limitations. Almost all of the athletes in this study
ere Caucasian. Of the small proportion of athletes of West
frican origin, 2 had features that could have been consis-
ent with HCM; however, subsequent evaluation was more
uggestive of physiological LVH. We have concerns that a
al T-Wave Inversions Before and After Detraining for 12 Weeks
rdiography and normalization of deep T-wave inversions after detraining.later
echocaore detailed study of cardiac structure is required in this
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March 11, 2008:1033–9 HCM in Elite Athletesarticular ethnic group to permit accurate cardiovascular
valuation and minimize the risk of a false-positive diagno-
is of HCM.
cknowledgments
he authors acknowledge the invaluable assistance of Car-
iac Risk in the Young (CRY) for providing the electrocar-
iography and echocardiography machines for the study.
eprint requests and correspondence: Dr. Sanjay Sharma, King’s
ollege Hospital, Denmark Hill, London, United Kingdom SE5
RS. E-mail: ssharma21@hotmail.com.
EFERENCES
1. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller
FO. Sudden death in young competitive athletes: clinical, demo-
graphic, and pathological profiles. JAMA 1996;276:199–204.
2. Maron BJ, Roberts WC, McAllister HA, Rosing DR, Epstein SE.
Sudden death in young athletes. Circulation 1980;62:218–22.
3. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:
1064–75.
4. Van Camp SP, Bloor CM, Mueller FO, Cantu RC, Olson HG. Non
traumatic sports death in high school and college athletes. Med Sci
Sports Exerc 1995;27:641–7.
5. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE.
Prevalence of hypertrophic cardiomyopathy in a general population of
young adults: echocardiographic analysis of 4111 subjects in the
CARDIA study. Circulation 1995;92:785–9.
6. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hyper-
trophic cardiomyopathy in young athletes. N Engl J Med 1998;339:
364–9.
7. Friedmann HH. Diagnostic Electrocardiography and Vecterocardio-
graphy. New York, NY: McGraw-Hill, 1971.
8. Bazett HC. An analysis of the time relations of electrocardiograms.
Heart 1920;7:353–67.
9. Sokolow M, Lyon TP. The ventricular complex in LV hypertrophy
obtained by unipolar precordial and limb leads. Am Heart J 1949;37:
161–86.
0. Tajik AJ, Seward JB, Hagler DJ, Mair DD, Lie JT. Two dimensional
real time ultrasound imaging of the heart and great vessels: technique,
image orientation, structure identification and validation. Mayo Clin
Proc 1978;53:271–303.
1. Sahn DJ, De Maria A, Krisslo J, Weyman A. Recommendations
regarding quantification of M-mode echocardiographic results of a
survey of echocardiographic measurements. Circulation 1978;58:
1072–85.
2. Spirito P, Maron BJ. Doppler echocardiography for assessing LV
diastolic function. Ann Intern Med 1988;109:122–6.
3. Maron BJ. Structural features of the athlete’s heart as defined by
echocardiogaphy. J Am Coll Cardiol 1986;7:190–203.
4. Pellicia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper
limit of physiological hypertrophy in highly trained elite athletes.
N Engl J Med 1991;324:295–301.
5. Sharma S, Maron BJ, Whyte G, Firoozi S, Elliott PM, McKenna WJ.
Physiologic limits of LV hypertrophy in elite junior athletes; relevance
to differential diagnosis of athletes heart and hypertrophic cardiomy-
opathy. J Am Coll Cardiol 2002;40:1431–6.
6. Maron BJ, Pellicia A, Spirito P. Cardiac disease in young trained
athletes. Insights into methods for distinguishing athletes heart from
structural heart disease, with particular emphasis on hypertrophic
cardiomyopathy. Circulation 1995;91:1596–601.
7. Lewis JF, Spirito P, Pellicia A, Maron BJ. Usefulness of Doppler
echocardiographic assessment of diastolic filling in distinguishing
“athlete’s heart” from hypertrophic cardiomyopathy. Br Heart J 1992;
68:296–300.
8. Basavarajaiah S, Makan J, Naghavi SH, Whyte G, Gati S, Sharma S.
Physiologic upper limits of left atrial diameter in highly trained
adolescent athletes. J Am Coll Cardiol 2006;47:2341–2.9. Pelliccia A, Maron BJ, Di Paolo FM, et al. Prevalence and clinical
significance of left atrial remodeling in competitive athletes. J Am Coll
Cardiol 2005;46:690–6.
0. Klues HG, Roberts WC, Maron BJ. Morphologic determinants of
echocardiographic patterns of mitral valve systolic anterior motion in
obstructive hypertrophic cardiomyopathy. Circulation 1993;87:
1570–9.
1. Savage DD, Seides SF, Clarke CE, et al. Electrocardiographic findings
in patients with obstructive and non obstructive hypertrophic cardio-
myopathy. Circulation 1986;58:402–8.
2. Maron BJ, Wolfson JK, Ciro E, Spirito P. Relation of electrocardio-
graphic abnormalities and patterns of hypertrophy identified by
2-dimensional echocardiography in patients with hypertrophic cardio-
myopathy. Am J Cardiol 1983;51:189.
3. Sharma S, Whyte G, Elliott P, et al. Electrocardiographic changes in
1000 highly trained junior elite athletes. Br J Sports Med 1999;33:319–
24.
4. Monseratt L, Elliott PM, Gimeno JR, et al. Non sustained ventricular
tachycardia in hypertrophic cardiomyopathy: an independent risk marker
of sudden death in young patients. J Am Coll Cardiol 2003;42:873–9.
5. Sharma S, Elliott PM, Whyte G, et al. Utility of cardiopulmonary
exercise in the assessment of clinical determinants of functional
capacity in hypertrophic cardiomyopathy. Am J Cardiol 2000;86:
162–8.
6. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical
Hypertrophic cardiomyopathy by magnetic resonance in patients with
non-diagnostic echocardiography. Heart 2004;90:645–9.
7. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic
cardiomyopathy: identification of high risk patients. J Am Coll Cardiol
2000;36:2212–8.
8. Maron BJ, Pelliccia A, Spataro A, Granata M. Reduction in LV wall
thickness after deconditioning in highly trained Olympic athletes. Br
Heart J 1993;69:125–8.
9. Ehsani AA, Hagberg JM, Hickson RC. Rapid changes in LV
dimensions and mass in response to physical conditioning and decon-
ditioning. Am J Cardiol 1978;42:52–6.
0. Basavarajaiah S, Wilson M, Junagde S, Jackson G, Whyte G, Sharma
S. Physiological LV hypertrophy or hypertrophic cardiomyopathy in
an elite adolescent athlete: role of detraining in resolving the clinical
dilemma. Br J Sports Med 2006;40:727–9.
1. Basavarajaiah S, Oxborough D, Wilson M, Sharma S. Incidental
finding of cor triatriatum in an asymptomatic elite athlete. J Am Soc
Echocardiogr 2007;20:771.e9–12.
2. Lewis JF, Maron BJ, Diggs JA, Spencer JE, Mehrotra PP, Curry CL.
Pre-participation echocardiographic screening for cardiovascular dis-
ease in a large, predominantly black population of collegiate athletes.
Am J Cardiol 1989;64:1029–33.
3. Jones S, Elliott PM, Sharma S, McKenna WJ, Whipp BJ. Cardiopul-
monary responses to exercise in patients with hypertrophic cardiomy-
opathy. Heart 1998;80:60–7.
4. Sharma S, Elliott PM, Whyte G, et al. Utility of metabolic exercise
testing in distinguishing hypertrophic cardiomyopathy from physio-
logic LV hypertrophy in athletes. J Am Coll Cardiol 2000;36:864–70.
5. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile,
and significance of LV remodelling in end stage phase of hypertrophic
cardiomyopathy. Circulation 2006;114:216–25.
6. Corrado D, Thiene G, Nava A, Rossi L, Pennelli N. Sudden death in
young competitive athletes: clinicopathologic correlations in 22 cases.
Am J Med 1990;89:588–96.
7. Maron BJ, Klues H. Surviving competitive athletics with hypertrophic
cardiomyopathy. Am J Cardiol 1994;73:1098–104.
8. Maron BJ, Niimura H, Casey SA, et al. Development of LV
hypertrophy in adults in hypertrophic cardiomyopathy caused by
cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol
2001;38:315–21.
9. Schwartz PJ, Moss AJ, Vincent G, Crampton RS. Diagnostic criteria
for the long QT syndrome. An uptodate. Circulation 1993;88:782–4.
0. Pelliccia A, Di Paolo FM, Corrado D, et al. Evidence for efficacy of
the Italian national pre-participation screening programme for iden-
tification of hypertrophic cardiomyopathy in competitive athletes. Eur
Heart J 2006;27:2196–200.
1. Corrado D, McKenna WJ. Appropriate interpretation of the athlete’s
electrocardiogram saves lives as well as money. Eur Heart J
2007;28:1920–2.
